{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:10:48Z","timestamp":1778850648211,"version":"3.51.4"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["603852"],"award-info":[{"award-number":["603852"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007721","name":"Cure SMA","doi-asserted-by":"publisher","award":["MER2021"],"award-info":[{"award-number":["MER2021"]}],"id":[{"id":"10.13039\/100007721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Spinal muscular atrophy (SMA) is a monogenic disease that clinically manifests as severe muscle weakness owing to neurotransmission defects and motoneuron degeneration. Individuals affected by SMA experience neuromuscular weakness that impacts functional activities of daily living. We have used a mouse model of severe SMA (SMN\u03947) to test whether a calcium channel gating modifier (GV-58), alone or in combination with a potassium channel antagonist (3,4-diaminopyridine; 3,4-DAP), can improve neuromuscular function in this mouse model. Bath application of GV-58 alone or in combination with 3,4-DAP significantly restored neuromuscular transmission to control levels in both a mildly vulnerable forearm muscle and a strongly vulnerable trunk muscle in SMN\u03947 mice at postnatal days 10\u201312. Similarly, acute subcutaneous administration of GV-58 to postnatal day 10 SMN\u03947 mice, alone or in combination with 3,4-DAP, significantly increased a behavioral measure of muscle strength. These data suggest that GV-58 may be a promising treatment candidate that could address deficits in neuromuscular function and strength and that the addition of 3,4-DAP to GV-58 treatment could aid in restoring function in SMA.<\/jats:p>","DOI":"10.1093\/hmg\/ddad019","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T23:47:08Z","timestamp":1675900028000},"page":"1901-1911","source":"Crossref","is-referenced-by-count":5,"title":["Potentiation of neuromuscular transmission by a small molecule calcium channel gating modifier improves motor function in a severe spinal muscular atrophy mouse model"],"prefix":"10.1093","volume":"32","author":[{"given":"Kristine S","family":"Ojala","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Center for Neuroscience, University of Pittsburgh , Pittsburgh, PA 15260 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra J","family":"Kaufhold","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Center for Neuroscience, University of Pittsburgh , Pittsburgh, PA 15260 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mykenzie R","family":"Davey","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Center for Neuroscience, University of Pittsburgh , Pittsburgh, PA 15260 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donggyun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Center for Neuroscience, University of Pittsburgh , Pittsburgh, PA 15260 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Pittsburgh , Pittsburgh, PA 15260 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wipf","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Pittsburgh , Pittsburgh, PA 15260 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yomna","family":"Badawi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Center for Neuroscience, University of Pittsburgh , Pittsburgh, PA 15260 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2005-9726","authenticated-orcid":false,"given":"Stephen D","family":"Meriney","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Center for Neuroscience, University of Pittsburgh , Pittsburgh, PA 15260 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"2023111214354810100_ref1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","article-title":"The neurobiology of childhood spinal muscular atrophy","volume":"3","author":"Crawford","year":"1996","journal-title":"Neurobiol. Dis."},{"key":"2023111214354810100_ref2","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy","volume":"17","author":"Kariya","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"2023111214354810100_ref3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","article-title":"Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice","volume":"29","author":"Kong","year":"2009","journal-title":"J. Neurosci."},{"key":"2023111214354810100_ref4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"2023111214354810100_ref5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/hmg\/ddm367","article-title":"Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy","volume":"17","author":"Murray","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"2023111214354810100_ref6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/hmg\/4.4.631","article-title":"Deletions in the survival motor neuron gene on 5q13 in autosomal recessive spinal muscular atrophy","volume":"4","author":"Rodrigues","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"2023111214354810100_ref7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ng0598-63","article-title":"SMN oligomerization defect correlates with spinal muscular atrophy severity","volume":"19","author":"Lorson","year":"1998","journal-title":"Nat. Genet."},{"key":"2023111214354810100_ref8","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2023111214354810100_ref9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0167-4781(99)00060-3","article-title":"Promoter analysis of the human centromeric and telomeric survival motor neuron genes (SMNC and SMNT)","volume":"1445","author":"Monani","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"2023111214354810100_ref10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"2023111214354810100_ref11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1086\/513913","article-title":"When is a deletion not a deletion? When it is converted","volume":"61","author":"Burghes","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"2023111214354810100_ref12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"Mailman","year":"2002","journal-title":"Genet. Med."},{"key":"2023111214354810100_ref13","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1086\/515465","article-title":"Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number","volume":"60","author":"McAndrew","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"2023111214354810100_ref14","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/hmg\/11.12.1439","article-title":"Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model","volume":"11","author":"Cifuentes-Diaz","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"2023111214354810100_ref15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mcn.2015.11.007","article-title":"Central and peripheral defects in motor units of the diaphragm of spinal muscular atrophy mice","volume":"70","author":"Neve","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"key":"2023111214354810100_ref16","doi-asserted-by":"crossref","first-page":"e26164","DOI":"10.1371\/journal.pone.0026164","article-title":"SMN requirement for synaptic vesicle, active zone and microtubule postnatal organization in motor nerve terminals","volume":"6","author":"Torres-Benito","year":"2011","journal-title":"PLoS One"},{"key":"2023111214354810100_ref17","first-page":"4703","article-title":"Synaptotagmin-2, and \u22121, linked to neurotransmission impairment and vulnerability in spinal muscular atrophy","volume":"25","author":"Tejero","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"2023111214354810100_ref18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00401-011-0848-5","article-title":"The spinal muscular atrophy mouse model, SMADelta7, displays altered axonal transport without global neurofilament alterations","volume":"122","author":"Dale","year":"2011","journal-title":"Acta Neuropathol."},{"key":"2023111214354810100_ref19","doi-asserted-by":"crossref","first-page":"e15457","DOI":"10.1371\/journal.pone.0015457","article-title":"Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy","volume":"5","author":"Ling","year":"2010","journal-title":"PLoS One"},{"key":"2023111214354810100_ref20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1523\/JNEUROSCI.4496-09.2010","article-title":"Altered intracellular Ca2+ homeostasis in nerve terminals of severe spinal muscular atrophy mice","volume":"30","author":"Ruiz","year":"2010","journal-title":"J. Neurosci."},{"key":"2023111214354810100_ref21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/joa.12038","article-title":"Neurotransmitter release in motor nerve terminals of a mouse model of mild spinal muscular atrophy","volume":"224","author":"Ruiz","year":"2014","journal-title":"J. Anat."},{"key":"2023111214354810100_ref22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1083\/jcb.200703187","article-title":"Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophy","volume":"179","author":"Jablonka","year":"2007","journal-title":"J. Cell Biol."},{"key":"2023111214354810100_ref23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hmg\/ddr453","article-title":"Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy","volume":"21","author":"Ling","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"2023111214354810100_ref24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"2023111214354810100_ref25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nmd.2018.10.001","article-title":"The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: results from trials in healthy adults and patients with spinal muscular atrophy","volume":"29","author":"Kletzl","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"2023111214354810100_ref26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"2023111214354810100_ref27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/gt.2017.34","article-title":"How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy","volume":"24","author":"Singh","year":"2017","journal-title":"Gene Ther."},{"key":"2023111214354810100_ref28","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci11020194","article-title":"In search of a cure: the development of therapeutics to Alter the progression of spinal muscular atrophy","volume":"11","author":"Ojala","year":"2021","journal-title":"Brain Sci."},{"key":"2023111214354810100_ref29","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2023111214354810100_ref30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2023111214354810100_ref31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nmd.2020.12.006","article-title":"Nusinersen treatment of older children and adults with spinal muscular atrophy","volume":"31","author":"Konersman","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"2023111214354810100_ref32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000164","article-title":"Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen","volume":"3","author":"Arnold","year":"2021","journal-title":"BMJ Neurol. Open"},{"key":"2023111214354810100_ref33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","article-title":"Risdiplam: a review in spinal muscular atrophy","volume":"36","author":"Paik","year":"2022","journal-title":"CNS Drugs"},{"key":"2023111214354810100_ref34","article-title":"Onasemnogene abeparvovec in type 1 spinal muscular atrophy: a systematic review and meta-analysis","author":"Pascual-Morena","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"2023111214354810100_ref35","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1113\/jphysiol.2014.276493","article-title":"Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist","volume":"592","author":"Tarr","year":"2014","journal-title":"J. Physiol."},{"key":"2023111214354810100_ref36","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1113\/jphysiol.2008.153569","article-title":"Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin a","volume":"586","author":"Rogozhin","year":"2008","journal-title":"J. Physiol."},{"key":"2023111214354810100_ref37","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1152\/jn.00168.2017","article-title":"Transmitter release site organization can predict synaptic function at the neuromuscular junction","volume":"119","author":"Laghaei","year":"2018","journal-title":"J. Neurophysiol."},{"key":"2023111214354810100_ref38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/joa.13228","article-title":"Morphological variability is greater at developing than mature mouse neuromuscular junctions","volume":"237","author":"Mech","year":"2020","journal-title":"J. Anat."},{"key":"2023111214354810100_ref39","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/joa.13478","article-title":"Dissection, in vivo imaging and analysis of the mouse epitrochleoanconeus muscle","volume":"241","author":"Villarroel-Campos","year":"2021","journal-title":"J. Anat."},{"key":"2023111214354810100_ref40","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/ejn.13249","article-title":"Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models","volume":"43","author":"Pijl","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"2023111214354810100_ref41","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/BF01187915","article-title":"Structure and function of the neuromuscular junction in young adult mdx mice","volume":"20","author":"Lyons","year":"1991","journal-title":"J. Neurocytol."},{"key":"2023111214354810100_ref42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1152\/physrev.00033.2014","article-title":"Mechanisms regulating neuromuscular junction development and function and causes of muscle wasting","volume":"95","author":"Tintignac","year":"2015","journal-title":"Physiol. Rev."},{"key":"2023111214354810100_ref43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/NEN.0000000000000144","article-title":"Spectrum of neuropathophysiology in spinal muscular atrophy type I","volume":"74","author":"Harding","year":"2015","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2023111214354810100_ref44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0896-6273(93)90110-D","article-title":"Gradual loss of synaptic cartels precedes axon withdrawal at developing neuromuscular junctions","volume":"11","author":"Balice-Gordon","year":"1993","journal-title":"Neuron"},{"key":"2023111214354810100_ref45","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"2023111214354810100_ref46","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"2023111214354810100_ref47","article-title":"Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep. Med."},{"key":"2023111214354810100_ref48","doi-asserted-by":"crossref","first-page":"10559","DOI":"10.1523\/JNEUROSCI.4629-12.2013","article-title":"Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome","volume":"33","author":"Tarr","year":"2013","journal-title":"J. Neurosci."},{"key":"2023111214354810100_ref49","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1113\/jphysiol.2001.013376","article-title":"Roscovitine: a novel regulator of P\/Q-type calcium channels and transmitter release in central neurons","volume":"540","author":"Yan","year":"2002","journal-title":"J. Physiol."},{"key":"2023111214354810100_ref50","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1111\/j.1471-4159.2008.05248.x","article-title":"The separation of antagonist from agonist effects of trisubstituted purines on CaV2.2 (N-type) channels","volume":"105","author":"Buraei","year":"2008","journal-title":"J. Neurochem."},{"key":"2023111214354810100_ref51","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.neuroscience.2010.02.041","article-title":"(R)-roscovitine prolongs the mean open time of unitary N-type calcium channel currents","volume":"167","author":"DeStefino","year":"2010","journal-title":"Neuroscience"},{"key":"2023111214354810100_ref52","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.100826","article-title":"R-Roscovitine improves Motoneuron function in mouse models for spinal muscular atrophy","volume":"23","author":"Tejero","year":"2020","journal-title":"iScience"},{"key":"2023111214354810100_ref53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.tins.2012.09.009","article-title":"Are unreliable release mechanisms conserved from NMJ to CNS?","volume":"36","author":"Tarr","year":"2013","journal-title":"Trends Neurosci."},{"key":"2023111214354810100_ref54","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1021\/ml3002083","article-title":"Synthesis and biological evaluation of a selective N- and p\/q-type calcium channel agonist","volume":"3","author":"Liang","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"2023111214354810100_ref55","doi-asserted-by":"crossref","first-page":"15224","DOI":"10.1073\/pnas.0507678102","article-title":"Aberrant motor axon projection, acetylcholine receptor clustering, and neurotransmission in cyclin-dependent kinase 5 null mice","volume":"102","author":"Fu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2023111214354810100_ref56","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.neuron.2005.04.002","article-title":"Neurotransmitter acetylcholine negatively regulates neuromuscular synapse formation by a Cdk5-dependent mechanism","volume":"46","author":"Lin","year":"2005","journal-title":"Neuron"},{"key":"2023111214354810100_ref57","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14656566.7.10.1323","article-title":"Available treatment options for the management of Lambert-Eaton myasthenic syndrome","volume":"7","author":"Verschuuren","year":"2006","journal-title":"Expert. Opin. Pharmacother."},{"key":"2023111214354810100_ref58","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol."},{"key":"2023111214354810100_ref59","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","article-title":"3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS","volume":"40","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"key":"2023111214354810100_ref60","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2020.07.007","article-title":"Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients","volume":"30","author":"Chiriboga","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"2023111214354810100_ref61","first-page":"260","article-title":"Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction","volume":"227","author":"Thomsen","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2023111214354810100_ref62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100302","article-title":"A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs","volume":"296","author":"Ojala","year":"2021","journal-title":"J. Biol. Chem."},{"key":"2023111214354810100_ref63","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann. Neurol."},{"key":"2023111214354810100_ref64","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0301-0082(00)00055-1","article-title":"Safety factor at the neuromuscular junction","volume":"64","author":"Wood","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"2023111214354810100_ref65","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fncel.2016.00276","article-title":"A novel striated muscle-specific myosin-blocking drug for the study of neuromuscular physiology","volume":"10","author":"Heredia","year":"2016","journal-title":"Front. Cell. Neurosci."},{"key":"2023111214354810100_ref66","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1113\/jphysiol.1981.sp013586","article-title":"Non-linear summation of end-plate potentials in the frog and mouse","volume":"311","author":"McLachlan","year":"1981","journal-title":"J. Physiol."}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/hmg\/advance-article-pdf\/doi\/10.1093\/hmg\/ddad019\/49344187\/ddad019.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hmg\/article-pdf\/32\/11\/1901\/53330100\/ddad019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hmg\/article-pdf\/32\/11\/1901\/53330100\/ddad019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T14:36:26Z","timestamp":1699799786000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/32\/11\/1901\/7033087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":66,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,2,9]]},"published-print":{"date-parts":[[2023,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddad019","relation":{},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,2,9]]}}}